227 related articles for article (PubMed ID: 36995071)
21. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
[TBL] [Abstract][Full Text] [Related]
22. Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade.
Yuan T; Qi B; Jiang Z; Dong W; Zhong L; Bai L; Tong R; Yu J; Shi J
Eur J Med Chem; 2019 Sep; 178():468-483. PubMed ID: 31207462
[TBL] [Abstract][Full Text] [Related]
23. Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
Yen SC; Chen LC; Huang HL; Ngo ST; Wu YW; Lin TE; Sung TY; Lien ST; Tseng HJ; Pan SL; Huang WJ; Hsu KC
J Nat Prod; 2021 Jan; 84(1):1-10. PubMed ID: 33393294
[TBL] [Abstract][Full Text] [Related]
24. Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations.
Long Y; Yu M; Ochnik AM; Karanjia JD; Basnet SK; Kebede AA; Kou L; Wang S
Eur J Med Chem; 2021 Mar; 213():113215. PubMed ID: 33516985
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of
Wu S; Edwards H; Wang D; Liu S; Qiao X; Carter J; Wang Y; Taub JW; Wang G; Ge Y
Cells; 2022 Sep; 11(17):. PubMed ID: 36078163
[No Abstract] [Full Text] [Related]
26. Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor.
Zhang L; Lakkaniga NR; Bharate JB; Mcconnell N; Wang X; Kharbanda A; Leung YK; Frett B; Shah NP; Li HY
Eur J Med Chem; 2021 Dec; 225():113776. PubMed ID: 34479037
[TBL] [Abstract][Full Text] [Related]
27. Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants.
Sun D; Yang Y; Lyu J; Zhou W; Song W; Zhao Z; Chen Z; Xu Y; Li H
J Med Chem; 2016 Jul; 59(13):6187-200. PubMed ID: 27266526
[TBL] [Abstract][Full Text] [Related]
28. Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia.
Liang X; Wang B; Chen C; Wang A; Hu C; Zou F; Yu K; Liu Q; Li F; Hu Z; Lu T; Wang J; Wang L; Weisberg EL; Li L; Xia R; Wang W; Ren T; Ge J; Liu J; Liu Q
J Med Chem; 2019 Jan; 62(2):875-892. PubMed ID: 30565931
[TBL] [Abstract][Full Text] [Related]
29. Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model.
Heng H; Wang Z; Li H; Huang Y; Lan Q; Guo X; Zhang L; Zhi Y; Cai J; Qin T; Xiang L; Wang S; Chen Y; Lu T; Lu S
Eur J Med Chem; 2019 Aug; 176():248-267. PubMed ID: 31103903
[TBL] [Abstract][Full Text] [Related]
30. A novel approach for relapsed/refractory FLT3
Li KX; Wu HY; Pan WY; Guo MQ; Qiu DZ; He YJ; Li YH; Yang DH; Huang YX
Mol Cancer; 2022 Mar; 21(1):66. PubMed ID: 35246156
[TBL] [Abstract][Full Text] [Related]
31. Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
Dokla EME; Abdel-Aziz AK; Milik SN; McPhillie MJ; Minucci S; Abouzid KAM
Bioorg Med Chem; 2022 Feb; 56():116596. PubMed ID: 35033885
[TBL] [Abstract][Full Text] [Related]
32. Targeting AML-associated FLT3 mutations with a type I kinase inhibitor.
Jones LM; Melgar K; Bolanos L; Hueneman K; Walker MM; Jiang JK; Wilson KM; Zhang X; Shen J; Jiang F; Sutter P; Wang A; Xu X; Tawa GJ; Hoyt SB; Wunderlich M; O'Brien E; Perentesis JP; Starczynowski DT; Thomas CJ
J Clin Invest; 2020 Apr; 130(4):2017-2023. PubMed ID: 32149729
[TBL] [Abstract][Full Text] [Related]
33. Discovery of a Potent and Selective FLT3 Inhibitor (
Wang J; Pan X; Song Y; Liu J; Ma F; Wang P; Liu Y; Zhao L; Kang D; Hu L
J Med Chem; 2021 Apr; 64(8):4870-4890. PubMed ID: 33797247
[TBL] [Abstract][Full Text] [Related]
34. Isoliquiritigenin, an Orally Available Natural FLT3 Inhibitor from Licorice, Exhibits Selective Anti-Acute Myeloid Leukemia Efficacy In Vitro and In Vivo.
Cao ZX; Wen Y; He JL; Huang SZ; Gao F; Guo CJ; Liu QQ; Zheng SW; Gong DY; Li YZ; Zhang RQ; Chen JP; Peng C
Mol Pharmacol; 2019 Nov; 96(5):589-599. PubMed ID: 31462456
[TBL] [Abstract][Full Text] [Related]
35. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
Pemmaraju N; Kantarjian H; Andreeff M; Cortes J; Ravandi F
Expert Opin Investig Drugs; 2014 Jul; 23(7):943-54. PubMed ID: 24749672
[TBL] [Abstract][Full Text] [Related]
36. FMS-like tyrosine kinase 3 (FLT3) inhibitors: Molecular docking and experimental studies.
Mashkani B; Tanipour MH; Saadatmandzadeh M; Ashman LK; Griffith R
Eur J Pharmacol; 2016 Apr; 776():156-66. PubMed ID: 26896780
[TBL] [Abstract][Full Text] [Related]
37. Beta Elemene induces cytotoxic effects in FLT3 ITD-mutated acute myeloid leukemia by modulating apoptosis.
Alafnan A; Dogan R; Bender O; Celik I; Mollica A; Malik JA; Rengasamy KRR; Break MKB; Khojali WMA; Alharby TN; Atalay A; Anwar S
Eur Rev Med Pharmacol Sci; 2023 Apr; 27(8):3270-3287. PubMed ID: 37140277
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive structure-activity-relationship of azaindoles as highly potent FLT3 inhibitors.
Grimm SH; Gagestein B; Keijzer JF; Liu N; Wijdeven RH; Lenselink EB; Tuin AW; van den Nieuwendijk AMCH; van Westen GJP; van Boeckel CAA; Overkleeft HS; Neefjes J; van der Stelt M
Bioorg Med Chem; 2019 Mar; 27(5):692-699. PubMed ID: 30661740
[TBL] [Abstract][Full Text] [Related]
39. Discovery of oxindole-based FLT3 inhibitors as a promising therapeutic lead for acute myeloid leukemia carrying the oncogenic ITD mutation.
Bender O; Shoman ME; Ali TFS; Dogan R; Celik I; Mollica A; Hamed MIA; Aly OM; Alamri A; Alanazi J; Ahemad N; Gan SH; Malik JA; Anwar S; Atalay A; Beshr EAM
Arch Pharm (Weinheim); 2023 Feb; 356(2):e2200407. PubMed ID: 36403191
[TBL] [Abstract][Full Text] [Related]
40. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with
Yamaura T; Nakatani T; Uda K; Ogura H; Shin W; Kurokawa N; Saito K; Fujikawa N; Date T; Takasaki M; Terada D; Hirai A; Akashi A; Chen F; Adachi Y; Ishikawa Y; Hayakawa F; Hagiwara S; Naoe T; Kiyoi H
Blood; 2018 Jan; 131(4):426-438. PubMed ID: 29187377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
